HARMONY BIOSCIENCES HOLDINGS (HRMY)

Company Profile

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company, which engages in the development and commercialization of therapies for the treatment of neurological disorders. The company is headquartered in Plymouth Meeting, Pennsylvania and currently employs 200 full-time employees. The company went IPO on 2020-08-19. The firm is focused on developing and commercializing therapies for patients living with rare neurological diseases, as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a molecule with a mechanism of action (MOA) specifically designed to increase histamine signaling in the brain by binding to H3 receptors. Its WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy and treatment of cataplexy in adult patients with narcolepsy. Its narcolepsy treatment works primarily through histamine, a major wake-promoting neurotransmitter. The firm also provides HBS-102, an investigational compound, which is a melanin-concentrating hormone (MCH) receptor 1 (MCHR1) antagonist that targets MCH neurons in the brain. Its product candidates also include Zygel, which is a synthetic cannabidiol.

Company Info

HARMONY BIOSCIENCES HOLDINGS

630 W Germantown Pike, Suite 215

Plymouth Meeting PENNSYLVANIA 19462

P: 14845399800

CEO: John C. Jacobs

Employees: 200

Website: https://www.harmonybiosciences.com/